Gastrointestinal Pathology
Gastric carcinoma is a malignant neoplasm arising from the epithelial cells of the stomach lining, representing the fifth most common cancer worldwide and the third leading cause of cancer-related mortality. The disease typically develops through a multistep process spanning years to decades, beginning with chronic inflammation and progressing through atrophic gastritis, intestinal metaplasia, and dysplasia before invasive carcinoma emerges. Understanding the molecular pathogenesis, risk factors, and clinical presentation of gastric cancer is essential for early detection, appropriate treatment selection, and improved patient outcomes. While incidence has declined in Western nations due to improved food preservation and reduced Helicobacter pylori infection rates, gastric carcinoma remains a major health burden in East Asia, Eastern Europe, and South America.
📋 Abbreviations Used in This Article
- H. pylori: Helicobacter pylori
- GIST: Gastrointestinal Stromal Tumor
- WHO: World Health Organization
- CDH1: Cadherin 1 gene (E-cadherin)
- TNM: Tumor, Node, Metastasis staging system
- CEA: Carcinoembryonic Antigen
- CA19-9: Cancer Antigen 19-9
- CT: Computed Tomography
- PET: Positron Emission Tomography
- HER2: Human Epidermal Growth Factor Receptor 2
- MSI-H: Microsatellite Instability-High
- dMMR: Deficient Mismatch Repair
- EBV: Epstein-Barr Virus
- VEGFR2: Vascular Endothelial Growth Factor Receptor 2
- FLOT: Fluorouracil, Leucovorin, Oxaliplatin, Docetaxel regimen
- XELOX: Capecitabine and Oxaliplatin regimen
- FOLFOX: Folinic acid, Fluorouracil, Oxaliplatin regimen
- PPI: Proton Pump Inhibitor
🔄 Classification and Types
Gastric carcinoma is classified based on histological patterns, with the Lauren classification being most widely used clinically:
Intestinal Type (Lauren Classification)
- Architecture: Forms cohesive gland-like structures
- Demographics: More common in older adults
- Etiology: Strongly associated with H. pylori infection
- Precursor Lesion: Intestinal metaplasia and dysplasia
- Prognosis: Better outcomes when detected early
- Epidemiology: Incidence declining worldwide
Diffuse Type (Lauren Classification)
- Architecture: Poorly cohesive cells infiltrate stomach wall
- Demographics: Affects younger patients more frequently
- Etiology: Genetic factors play larger role
- Genetics: Associated with E-cadherin (CDH1) mutations
- Prognosis: Generally poorer outcomes, aggressive behavior
- Epidemiology: Incidence stable or increasing
🌍 Geographic Variation: Gastric cancer incidence demonstrates dramatic geographic disparities. Rates in East Asia (Japan, Korea, China), Eastern Europe, and South America are 5 to 10 times higher than in North America and most of Africa. This pattern underscores the critical role of environmental and dietary factors in disease pathogenesis.
🧬 Pathogenesis: The Correa Cascade
Intestinal-type gastric cancer typically follows the Correa cascade, a well-defined sequence of histological changes:
Stage 1: Chronic Gastritis
- Cause: H. pylori infection, autoimmune disease
- Mechanism: Persistent inflammatory cell infiltration
- Duration: Years to decades of ongoing inflammation
- Reversibility: Potentially reversible with H. pylori eradication
Stage 2: Atrophic Gastritis
- Change: Loss of normal gastric glands
- Function: Reduced acid production (hypochlorhydria)
- Associated Condition: Pernicious anemia
- Risk: 2 to 3-fold increased cancer risk
Stage 3: Intestinal Metaplasia
- Transformation: Gastric epithelium replaced by intestinal-type cells
- Types: Complete (absorptive) versus incomplete (secretory)
- Risk: Incomplete type has higher malignant potential
- Significance: Critical precursor lesion
Stage 4: Dysplasia
- Low-Grade: Mild architectural and cytological atypia
- High-Grade: Severe atypia, carcinoma in situ
- Progression: 10% to 25% advance to invasive cancer
- Management: Requires intervention or close surveillance
🔬 Clinical Insight: The Correa cascade provides multiple intervention points for cancer prevention. H. pylori eradication during chronic gastritis stage can halt progression. Once intestinal metaplasia develops, surveillance programs enable early cancer detection when curative treatment is still possible.
⚠️ Risk Factors
Understanding risk factors enables identification of high-risk individuals for targeted screening and prevention:
Major Risk Factors for Gastric Carcinoma
- H. pylori Infection: Most important risk factor, classified as Class I carcinogen by WHO
- Diet: High salt, smoked foods, nitrates; low fruits and vegetables
- Tobacco Smoking: 1.5 to 2.5-fold increased risk
- Chronic Atrophic Gastritis: Precursor lesion with 2 to 3-fold increased risk
- Pernicious Anemia: Autoimmune condition causing gastric atrophy
- Previous Gastric Surgery: Partial gastrectomy increases risk after 15 to 20 years
- Family History: 2 to 3-fold increased risk with affected first-degree relative
- Genetic Syndromes: Hereditary diffuse gastric cancer (CDH1 mutation), Lynch syndrome
- EBV Infection: Found in approximately 10% of gastric cancers
| Risk Factor | Relative Risk | Mechanism | Prevention Strategy |
|---|---|---|---|
| H. pylori Infection | 3 to 6 times | Chronic inflammation, oxidative damage | Antibiotic eradication therapy |
| Smoking | 1.5 to 2.5 times | Carcinogens, mucosal damage | Tobacco cessation |
| High Salt Diet | 2 times | Mucosal injury, enhances H. pylori virulence | Dietary modification, limit processed foods |
| Family History | 2 to 3 times | Genetic susceptibility, shared environment | Genetic counseling, screening |
| Pernicious Anemia | 2 to 3 times | Chronic atrophic gastritis, achlorhydria | Endoscopic surveillance |
🎯 H. pylori Significance: WHO classifies H. pylori as a Class I carcinogen. Eradication therapy reduces gastric cancer risk by 35% to 50%, representing one of the most effective cancer prevention strategies available. Population-based H. pylori screening and treatment programs in high-incidence regions show significant cancer reduction.
🤒 Clinical Presentation
Early gastric cancer often remains asymptomatic or produces vague symptoms easily attributed to benign conditions. Advanced disease presents with more specific and alarming features:
| Symptom Category | Early Stage | Advanced Stage | Clinical Significance |
|---|---|---|---|
| Abdominal Symptoms | Mild dyspepsia, bloating | Persistent pain, early satiety, vomiting | Often mistaken for peptic ulcer disease |
| Systemic Symptoms | None or minimal fatigue | Weight loss, cachexia, severe fatigue | Indicates advanced disease or metastasis |
| Bleeding | Occult blood loss | Hematemesis, melena, severe anemia | May be presenting sign of advanced cancer |
| Obstructive Symptoms | Absent | Dysphagia, persistent vomiting | Tumor at cardia or pylorus |
| Metastatic Signs | None | Jaundice, ascites, bone pain | Indicates liver, peritoneal, or bone metastases |
Alarm Symptoms Requiring Evaluation
- Unexplained weight loss (greater than 5% body weight)
- Persistent or progressive dysphagia
- Persistent vomiting
- Evidence of gastrointestinal bleeding
- Iron deficiency anemia without clear source
- Palpable abdominal mass
- Jaundice or ascites
- New-onset dyspepsia in patients over 55 years
Physical Examination Findings
- Virchow's Node: Left supraclavicular lymphadenopathy
- Sister Mary Joseph Node: Periumbilical metastatic nodule
- Irish Node: Left anterior axillary lymphadenopathy
- Krukenberg Tumor: Ovarian metastases (bilateral)
- Blumer's Shelf: Rectal shelf from peritoneal metastases
- Hepatomegaly: Liver metastases
- Ascites: Peritoneal carcinomatosis
🔍 Diagnosis and Staging
Accurate diagnosis and staging are critical for treatment planning and prognostic assessment:
Diagnostic Procedures
- Upper Endoscopy: Gold standard with direct visualization
- Multiple Biopsies: Minimum 7 samples from suspicious areas
- Endoscopic Ultrasound: Assesses depth of invasion (T stage)
- CT Scan: Evaluates local extension and metastases
- PET-CT: Detects distant metastatic disease
- Diagnostic Laparoscopy: Identifies peritoneal metastases
- Tumor Markers: CEA, CA19-9 for monitoring response
TNM Staging System
- T Stage: Depth of tumor invasion into gastric wall
- N Stage: Number and location of involved lymph nodes
- M Stage: Presence of distant metastases
- Stage 0: Carcinoma in situ (Tis N0 M0)
- Stage I-II: Early disease, potentially curable
- Stage III: Locally advanced, curative intent treatment
- Stage IV: Metastatic disease, palliative treatment
📊 Biopsy Protocol: Multiple biopsies (minimum 7) should be obtained from suspicious lesions, including ulcer margins and base. For large lesions, samples from different areas are essential because gastric cancers can demonstrate histological heterogeneity within a single tumor.
💊 Treatment Approaches
Treatment is multimodal and stage-dependent, requiring multidisciplinary team coordination:
| Stage | Primary Treatment | 5-Year Survival | Treatment Goals |
|---|---|---|---|
| Stage 0 to I | Endoscopic resection or surgery alone | 70% to 95% | Curative |
| Stage II | Surgery with adjuvant chemotherapy | 35% to 60% | Curative |
| Stage III | Neoadjuvant chemotherapy, surgery, adjuvant chemotherapy | 15% to 40% | Curative intent |
| Stage IV | Palliative chemotherapy, targeted therapy, immunotherapy | Less than 5% | Palliation, survival prolongation |
Surgical Options
- Endoscopic Mucosal Resection: Early cancer confined to mucosa
- Subtotal Gastrectomy: Distal tumors, preserves proximal stomach
- Total Gastrectomy: Proximal or diffuse tumors
- D2 Lymphadenectomy: Removal of regional lymph node stations
- Palliative Surgery: Gastrojejunostomy bypass, stent placement
Systemic Therapies
- Chemotherapy: Fluorouracil, cisplatin, oxaliplatin, taxanes
- Targeted Therapy: Trastuzumab (HER2-positive), ramucirumab (VEGFR2)
- Immunotherapy: Pembrolizumab (MSI-H/dMMR tumors)
- Combination Regimens: FLOT, XELOX, FOLFOX protocols
- Supportive Care: Pain management, nutritional support
🎯 Surgical Advances: Minimally invasive techniques (laparoscopic and robotic surgery) are increasingly utilized for gastric cancer resection. These approaches offer comparable oncologic outcomes with reduced postoperative pain, faster recovery, and shorter hospitalization compared to traditional open surgery.
📊 Prognosis and Survival
Prognosis depends primarily on stage at diagnosis, with dramatic survival differences between early and advanced disease:
Prognostic Factors
- Stage at Diagnosis: Most important prognostic factor
- Lymph Node Status: Number of positive nodes correlates with survival
- Depth of Invasion: T stage in TNM classification
- Histological Type: Intestinal versus diffuse pattern
- Resection Margins: R0 (negative) versus R1/R2 (positive)
- Molecular Markers: HER2, MSI, EBV status
- Patient Factors: Age, performance status, comorbidities
Survival by Stage
- Stage IA: 90% to 95% five-year survival
- Stage IB: 80% to 85% five-year survival
- Stage II: 35% to 60% five-year survival
- Stage IIIA: 25% to 40% five-year survival
- Stage IIIB/C: 10% to 25% five-year survival
- Stage IV: Less than 5% five-year survival
- Overall: Approximately 30% five-year survival (all stages)
🌍 Screening Impact: In countries with established screening programs (Japan, South Korea), over 50% of gastric cancers are diagnosed at early stages, resulting in five-year survival rates exceeding 70%. This contrasts with Western countries where most cases present at advanced stages, with overall survival around 30%.
🛡️ Prevention and Screening
Prevention and early detection strategies can significantly reduce gastric cancer mortality, particularly in high-risk populations:
| Strategy | Target Population | Intervention | Evidence Level |
|---|---|---|---|
| H. pylori Eradication | All infected individuals in high-risk areas | Triple therapy: PPI plus two antibiotics | Strong evidence for 35% to 50% risk reduction |
| Dietary Modification | General population | Increase fruits/vegetables, reduce salt and smoked foods | Moderate evidence |
| Tobacco Cessation | All smokers | Complete tobacco avoidance | Strong evidence |
| Endoscopic Screening | High-risk populations (Asia, family history) | Upper endoscopy with biopsy protocol | Strong evidence in high-incidence regions |
| Surveillance | Patients with atrophic gastritis, intestinal metaplasia | Periodic endoscopy based on risk stratification | Moderate evidence |
🎯 Screening Success: South Korea's national gastric cancer screening program offers upper endoscopy or upper gastrointestinal series every two years for adults over 40 years. This program has increased early-stage diagnoses to over 60% and reduced gastric cancer mortality by more than 50% over two decades.
🎯 Clinical Pearls
Essential considerations for understanding and managing gastric carcinoma:
- Gastric cancer is the fifth most common cancer and third leading cause of cancer deaths globally
- H. pylori infection accounts for approximately 90% of non-cardia gastric cancers
- Early gastric cancer is often asymptomatic; symptoms typically indicate advanced disease
- The Correa cascade provides multiple intervention points for cancer prevention
- Screening programs in high-incidence countries demonstrate significant mortality reduction
- Stage at diagnosis is the most important prognostic factor
- H. pylori eradication reduces gastric cancer risk by 35% to 50%
- Multimodal therapy (surgery plus chemotherapy) is standard for stages II and III
🔬 Pathology Study Tips:
- Master the Correa cascade: Chronic gastritis, atrophic gastritis, intestinal metaplasia, dysplasia, carcinoma
- Know Lauren classification: Intestinal (cohesive, older patients) versus diffuse (infiltrative, younger patients)
- Understand staging: TNM system determines treatment and prognosis
- Remember eponymous signs: Virchow's node, Krukenberg tumor, Sister Mary Joseph node